The goal of the NIDDK-sponsored Diabetic Complications Consortium (DiaComp) is to provide an environment that will foster communication and collaboration between investigator communities involved in complications research. The DiaComp-PTP will provide investigators with access to pilot funds to pursue additional preclinical studies of promising new therapeutics.
Funding Opportunities
| Title | FOA | Post | Expire | Purpose | |
|---|---|---|---|---|---|
NIDDK |
Request for Information (RFI): Research Strategies for Addressing Obesity Heterogeneity | NOT-DK-24-026 | 2024-09-24 | 2024-11-29 | This Request for Information (RFI) invites input on research strategies to address obesity heterogeneity. It is intended to solicit input from a broad array of interested individuals, groups and communities including the biomedical and behavioral research community, physicians and other health care professionals, industry, and other interested parties including public health or social service officials at the federal, state, county and community levels, community organizations, those in educational settings, payers, media, advocacy groups and the general public. |
NIDDK |
HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment | RFA-NS-22-034 | 2022-02-02 | 2024-12-07 | The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. |
NIDDK |
Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) | PAR-22-111 | 2022-02-04 | 2025-01-08 | The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. |
NIDDK |
Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases | NOT-DK-23-021 | 2023-10-30 | 2025-02-07 | The purpose of the NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians. |
NIDDK |
NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed) | PAR-22-171 | 2022-06-29 | 2025-06-27 | The NIDDK Central Repository houses valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at the Repository's website. |
| AMP-CMD Opportunity Pool Funding Opportunity Announcement 2021 | 2021-09-10 | 2025-06-30 | The current 5-year AMP-CMD award includes funding for an annual opportunity pool (OP) to support projects to address research directions that would further consortium goals but are not currently ongoing in the consortium. The OP funds are allocated from the NIDDK limited competition award (UM1DK105554), and OP project awards are administered by the Broad Institute. In the first round (Fall 2021), applications for years 1 and 2 are being considered. | ||
NIDDK |
Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional) | PAR-23-112 | 2023-01-31 | 2026-01-08 | This initiative will support intervention research to address the impact of SRD on minority health and health disparities. Research projects must address SRD in one or more NIH-designated populations with health disparities in the US and should address documented disparities in health outcomes. |
ADA |
Innovative Research to Improve the Lives of Women with Diabetes Across the Lifespan | 2022-09-19 | 2026-03-31 | ADA is soliciting proposals for research to better understand clinically important sex and gender differences to optimally inform prevention, diagnosis and treatment strategies for women across the lifespan and the development of sex-specific clinical guidelines where warranted. | |
ADA |
Innovative Research to Support the Psychological and Emotional Needs of People with Diabetes | 2022-09-19 | 2026-03-31 | ADA is soliciting proposals for interventional, generalizable and scalable research to better understand and address how to improve all aspects of the integration of mental health care into clinical settings serving people with diabetes, especially for disadvantaged lower socioeconomic level familie | |
ADA |
Innovative Research to Tackle the Epidemic of Youth-Onset Type 2 Diabetes | 2022-09-19 | 2026-03-31 | ADA is soliciting proposals to address key knowledge gaps in youth-onset T2D in order to better understand, prevent, treat, and ultimately induce remission for the rapidly increasing numbers of affected individuals. | |
NIDDK |
Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required) | PAS-23-086 | 2023-03-06 | 2026-05-08 | This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. |